Search results for " Hormonal"

showing 10 items of 68 documents

Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Reg…

2018

Recent evidence supports the concept that progression of chronic heart failure (CHF) depends upon an imbalance of catabolic forces over the anabolic drive. In this regard, multiple hormonal deficiency syndrome (MHDS) significantly has impacts upon CHF progression, and is associated with a worse clinical status and increased mortality. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Therapy in Heart Failure) Registry (clinicaltrial.gov = NCT02335801) tests the hypothesis that anabolic deficiencies reduce survival in a large population of mild-to-moderate CHF patients. The T.O.S.CA. Registry is a prospective multicenter observational study coordinated by “Federico II” Un…

MaleAnabolismmedicine.medical_treatment030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawClinical endpointMedicineDeficiency Disease030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyTestosteroneAnabolic deficiency; Chronic heart failure; Heart failure metabolism; Multiple hormonal deficiency syndrome; Registry; Aged; Biomarkers; Chronic Disease; Deficiency Diseases; Disease Progression; Female; Heart Failure; Humans; Italy; Male; Metabolic Diseases; Middle Aged; Prospective Studies; Registries; Internal Medicine; Emergency MedicineMiddle AgedItalyEmergency MedicineDisease ProgressionFemaleHumanmedicine.medical_specialtyRegistryAnabolic deficiencyAnabolic deficiency Chronic heart failure Heart failure metabolism Multiple hormonal deficiency syndrome RegistrySocio-culturaleHeart failure metabolism03 medical and health sciencesMetabolic DiseasesInternal medicineInternal MedicineHumansAgedHeart Failurebusiness.industryMultiple hormonal deficiency syndromeSettore MED/13 - ENDOCRINOLOGIABiomarkermedicine.diseaseChronic heart failureMetabolic DiseaseProspective StudieHeart failureChronic DiseaseObservational studyHormone therapybusinessDeficiency DiseasesBiomarkersInternal and emergency medicine
researchProduct

Evaluation of thermoresponsive properties and biocompatibility of polybenzofulvene aggregates for leuprolide delivery

2012

Abstract In this study, a polybenzofulvene derivative named poly-6-MOEG-9-BF3k, was evaluated as polymeric material for the production of injectable thermoresponsive nano-aggregates able to load low molecular weight peptidic drug, like the anticancer leuprolide. Thermoresponsive behavior of poly-6-MOEG-9-BF3k was studied in aqueous media by evaluating scattering intensity variations by means of DLS in function of temperature. Zeta potential measurements and SEM observations were also carried out. Moreover, critical aggregation temperature of the poly-6-MOEG-9-BF3k polymer was evaluated by pyrene fluorescence analysis. Then, the ability of prepared thermoresponsive aggregates to protect this…

MaleAntineoplastic Agents HormonalBiocompatibilityCell SurvivalPolymersPharmaceutical ScienceNanotechnologyCell Linechemistry.chemical_compoundAnimal modelIn vivoZeta potentialAnimalsHumansRats WistarThermoresponsiveSkinchemistry.chemical_classificationDrug CarriersOligopeptideChemistryTemperaturePolymerNano-aggregateIn vitroNanostructuresRatsIndenesSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoMicroscopy Electron ScanningBiophysicsPyrenePolybenzofulveneLeuprolideInternational Journal of Pharmaceutics
researchProduct

Fluorinated and pegylated polyaspartamide derivatives to increase solubility and efficacy of Flutamide

2012

New fluorinated amphiphilic copolymers based on a biocompatible polyaspartamide have been prepared in order to obtain polymeric micelles useful for delivering anticancer drugs. In particular, α,β-poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA) has been derivatized with polyethylene glycol (PEG(2000)) and ethylendiamine (EDA). Both these portions form the hydrophilic part of the copolymer, while the hydrophobic moiety is given by 1,2,4-oxadiazoles: 5-pentafluorophenyl-3-perfluoroheptyl-1,2,4-oxadiazole (PPOX) or 3-carboxyethyl-5-pentadecafluoroheptyl-1,2,4-oxadiazole (CPOX). Copolymers named PHEA-PEG(2000)-EDA-PPOX and PHEA-PEG(2000)-EDA-CPOX have been prepared with various degrees of derivati…

MaleAntineoplastic Agents HormonalPolymersSize-exclusion chromatographyPharmaceutical SciencePolyethylene glycolAdenocarcinomaPolyethylene Glycolschemistry.chemical_compoundDrug Delivery SystemsCell Line TumorPolymer chemistryCopolymerHumansSolubilityDerivatizationMicellesCell Proliferationchemistry.chemical_classificationDrug CarriersOxadiazolesProstatic NeoplasmsDihydrotestosteroneSettore CHIM/06 - Chimica OrganicaPolymerEthylenediaminesFlutamideCancer targeting cell model colloidal particles drug delivery polymerSolubilitychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryChromatography GelMicroscopy Electron ScanningPyrenePeptidesHydrophobic and Hydrophilic InteractionsJournal of Drug Targeting
researchProduct

Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor

1990

Abstract Some progestogens widely used in oral contraceptives are characterized at the level of high-affinity receptor binding as well as binding to sex hormone-binding globulin and corticosteroid-binding globulin. With regard to binding to sex hormone-binding globulin, gestodene, levonorgestrel, and to a lesser extent 3-ketodesogestrel (which is only formed from the prodrug desogestrel in the body), show a behavior that is manifested in the relatively high affinity to sex hormone-binding globulin, whereas desogestrel and norgestimate do not display any measurable affinity for this specific steroid-binding serum protein. Furthermore, levonorgestrel and gestodene dissociate very much more sl…

MaleCytoplasmmedicine.medical_specialtyNorpregnenesmedicine.medical_treatmentReceptors Cell SurfaceLevonorgestrelCytoplasmic receptorGestodeneBinding CompetitiveContraceptives Oral HormonalSex hormone-binding globulinPregnancyDesogestrelSex Hormone-Binding GlobulinInternal medicineNorgestrelmedicineAnimalsHumansLevonorgestrelProgesteroneTranscortinDesogestrelProgesterone CongenersProgestogenbiologybusiness.industryNorgestrelUterusObstetrics and GynecologyRats Inbred StrainsBlood ProteinsNorgestimateRatsKineticsEndocrinologybiology.proteinFemaleProgestinsbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugAmerican Journal of Obstetrics and Gynecology
researchProduct

Hormonal, auxological and clinical follow-up in children with connatal HIV infection: personal records

2006

Auxological and endocrinological complications frequently occur in children with connatal HIV infection. These complications seem to be related both to the infection itself and the antiretroviral therapy. Many children consequently show height-weight and pubertal retardation without any evidence of hormonal deficit. We studied 10 children with connatal HIV infection who were enrolled in this analysis and followed up for 7 years in order to evaluate their height-weight growth, pubertal maturation, bone age progression and hormonal pattern [basal Growth hormone (GH) and GH after Clonidine or Insulin stimulation, Insulin-like Growth Factor 1 (IGF-1), Insulin-like Growth Factor Binding Protein …

MaleHIV hormonal follow-up auxological follow-up clinical follow-upSettore MED/17 - Malattie InfettiveBody WeightInfant NewbornInfantHIV InfectionsChild DevelopmentSettore MED/38 - Pediatria Generale E SpecialisticaChild PreschoolBody SizeHumansFemaleLongitudinal StudiesChildFollow-Up Studies
researchProduct

Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis

2014

The EGFR/PI3K/PTEN/Akt/mTORC pathway plays prominent roles in malignant transformation, prevention of apoptosis, drug resistance, cancer initiating cells (CICs) and metastasis. The expression of this pathway is frequently altered in breast and other cancers due to mutations at or aberrant expression of: HER2, EGFR1, PIK3CA, and PTEN as well as other oncogenes and tumor suppressor genes. miRs and epigenetic mechanisms of gene regulation are also important events which regulate this pathway. In some breast cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are associated with a better prognosis than breast cancers lacking these mutations. The expression of this pathw…

MaleOncologyCancer Researchmedicine.medical_treatmentTargeted therapyMetastasisTargeted therapyBreast cancerNeoplasmsNeoplasm MetastasisCancer stem cellsMedicine (all)Neoplasm ProteinsNeoplasm MetastasiGene Expression Regulation NeoplasticCell Transformation NeoplasticMolecular MedicineFemaleHormonal therapyHumanSignal Transductionmedicine.medical_specialtyEGFRBiologyNeoplasm ProteinBreast cancerGeneticCancer stem cellInternal medicineHER2GeneticsmedicineAnimalsHumansPTENMolecular BiologyProtein kinase BPI3K/AKT/mTOR pathwayCell ProliferationAnimalCancer stem cellTherapy resistanceCancermedicine.diseaseERDrug Resistance NeoplasmBreast cancer; Cancer stem cells; EGFR; ER; HER2; Hormonal therapy; Targeted therapy; Therapy resistancebiology.proteinCancer researchNeoplasm
researchProduct

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?

2014

Even in the current era of dose-escalated radiotherapy for prostate cancer, biochemical recurrence is not uncommon. Furthermore, biochemical failure is not specific to the site of recurrence. One of the major challenges in the management of prostate cancer patients with biochemical failure after radiotherapy is the early discrimination between those with locoregional recurrence only and those with metastatic disease. While the latter are generally considered incurable, patients with locoregional disease may benefit from emerging treatment options. Ultimately, the objective of salvage therapy is to control disease while ensuring minimal collateral damage, thereby optimizing both cancer and t…

MaleQuality ControlOncologyBiochemical recurrencemedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBrachytherapyBrachytherapySalvage therapyBone Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineAdenocarcinomaRadiosurgeryMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineManagement of prostate cancerProstate cancerInternal medicinemedicineHumansMulticenter Studies as TopicRadiology Nuclear Medicine and imagingComputingMilieux_MISCELLANEOUSProstatectomySalvage TherapyLymphatic Irradiationbusiness.industryPalliative CareProstatic NeoplasmsCancerAndrogen AntagonistsRadiotherapy DosageProstate-Specific Antigenmedicine.diseaseCombined Modality Therapy3. Good healthRadiation therapyProstate-specific antigenOncologyLymphatic MetastasisDose Fractionation RadiationRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessRadiotherapy Image-Guided
researchProduct

Survival of Mycosis Fungoides in Patients in the Southeast of England

2004

<i>Background:</i> Mycosis fungoides (MF) is the most common skin lymphoma. The aetiology of MF remains unknown, and no therapy has to date significantly altered patient survival. <i>Objective:</i> The present study examines trends in survival of MF patients in a well-defined population-based disease group, namely patients registered over a 40-year period at the Thames Cancer Registry, Southeast England. <i>Methods:</i> The Thames Cancer Registry is a population-based registry, covering a population of approximately 14 million people. Data were taken from the Surveillance, Epidemiology and End Results cancer registry programme and the National Centre for …

Malemedicine.medical_specialtyPathologySkin NeoplasmsAntineoplastic Agents HormonalDermatologyCohort StudiesMycosis FungoidesSex FactorsResidence CharacteristicsEpidemiologymedicineHumansSezary SyndromeIn patientRegistriesSurvival rateAgedProportional Hazards ModelsMycosis fungoidesbusiness.industryProportional hazards modelAge FactorsMiddle AgedPrognosismedicine.diseaseDermatologyPeripheral T-cell lymphomaLymphomaSurvival RateEnglandPopulation SurveillanceEtiologyFemalebusinessFollow-Up StudiesSEER Program
researchProduct

Expression pattern of estroprogestinic receptors in sinonasal inverted papilloma

2017

// Agostino Serra 1 , Rosario Caltabiano 2 , Giacomo Spinato 3 , Salvatore Gallina 4 , Salvatore Caruso 5 , Venerando Rapisarda 6 , Paola Di Mauro 1 , Veronica Castro 1 , Angelo Conti 1 , Luisa Licciardello 1 , Luigi Maiolino 1 , Salvatore Lanzafame 2 , Salvatore Cocuzza 1 1 Department of Medical and Surgical Sciences and Advanced Technologies “G. Ingrassia”, ENT Section, University of Catania, Catania, Italy 2 Department of Medical and Surgical Sciences and Advanced Technologies “G. Ingrassia”, Section of Anatomic Pathology, University of Catania, Catania, Italy 3 ENT Department, Rovigo Provincial Hospital, Rovigo, Italy 4 Department of Experimental Biomedicine and Clinical Neurosciences, …

Malemedicine.medical_specialtyReceptor expressionNose NeoplasmsInverted papillomaMalignancyBenign tumor03 medical and health sciencesinverted papilloma0302 clinical medicineHuman papilloma viruhuman papilloma virusmedicineBiomarkers TumorHormonal receptor expression; Human papilloma virus; Immunohistochemistry; Inverted papilloma; Paranasal sinuses; OncologyHumanshormonal receptor expression030223 otorhinolaryngologyAgedRetrospective StudiesPapilloma Invertedbusiness.industryGeneral surgeryAnatomical pathologyMiddle Agedmedicine.diseaseSurgeryParanasal sinusesmedicine.anatomical_structureParanasal sinuseOtorhinolaryngologyOncologyReceptors EstrogenParanasal sinuses inverted papilloma human papilloma virus hormonal receptor expression immunohistochemistry030220 oncology & carcinogenesisimmunohistochemistryEtiologyFemaleNeoplasm Recurrence LocalbusinessReceptors ProgesteroneParanasal sinusesResearch Paper
researchProduct

Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive b…

2021

Abstract Breast Cancer (BC) is a leading cause of death in women, currently affecting 13% of female population worldwide. First-line clinical treatments against Estrogen Receptor positive (ER+) BC rely on suppressing estrogen production, by inhibiting the aromatase (AR) enzyme, or on blocking estrogen-dependent pro-oncogenic signaling, by targeting Estrogen Receptor (ER) α with selective Modulators/Degraders (SERMs/SERDs). The development of dual acting molecules targeting AR and ERα represents a tantalizing alternative strategy to fight ER + BC, reducing the incidence of adverse effects and resistance onset that limit the effectiveness of these gold-standard therapies. Here, in silico desi…

Molecular dynamicAntineoplastic Agents Hormonalmedicine.drug_classIn silicoEstrogen receptorBreast NeoplasmsMolecular dynamicsQM/MMBreast cancerbreast cancerDrug DiscoverymedicineHumansAromataseIC50Pharmacologychemistry.chemical_classificationbiologyAromatase InhibitorsMultitargetOrganic ChemistryEstrogen AntagonistsAromatase inhibitorGeneral Medicinemedicine.diseaseSERMEnzymechemistryEstrogenCell cultureSettore CHIM/03 - Chimica Generale E InorganicaSERDbiology.proteinCancer researchFemale
researchProduct